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Abstract
Background: Adjustable gene expression is crucial in a number of applications such as de- or
transdifferentiation of cell phenotypes, tissue engineering, various production processes as well as
gene-therapy initiatives. Viral vectors, based on the Adeno-Associated Virus (AAV) type 2, have
emerged as one of the most promising types of vectors for therapeutic applications due to
excellent transduction efficiencies of a broad variety of dividing and mitotically inert cell types and
due to their unique safety features.
Results: We designed recombinant adeno-associated virus (rAAV) vectors for the regulated
expression of transgenes in different configurations. We integrated the macrolide-responsive
E.REX systems (EON and EOFF) into rAAV backbones and investigated the delivery and expression
of intracellular as well as secreted transgenes for binary set-ups and for self- and auto-regulated
one-vector configurations. Extensive quantitative analysis of an array of vectors revealed a high
level of adjustability as well as tight transgene regulation with low levels of leaky expression, both
crucial for therapeutical applications. We tested the performance of the different vectors in
selected biotechnologically and therapeutically relevant cell types (CHO-K1, HT-1080, NHDF,
MCF-7). Moreover, we investigated key characteristics of the systems, such as reversibility and
adjustability to the regulating agent, to determine promising candidates for in vivo studies. To
validate the functionality of delivery and regulation we performed in vivo studies by injecting
particles, coding for compact self-regulated expression units, into mice and adjusting transgene
expression.
Conclusion: Capitalizing on established safety features and a track record of high transduction
efficiencies of mammalian cells, adeno- associated virus type 2 were successfully engineered to
provide new powerful tools for macrolide-adjustable transgene expression in mammalian cells as
well as in mice.
Background
An array of different viral transduction systems are being
used currently in pre-clinical and clinical trials [1-3].
Among these, vectors based on the replication-defective
adeno-associated virus type 2 have attracted special atten-
tion as tools for clinical gene transfer. Different character-
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istics, such as (i) the ability to transduce dividing as well
as non-dividing cells, (ii) high transduction rates in a wide
range of tissues, and notably, (iii) the unique safety prop-
erties, make AAVs a promising vector in gene therapy ini-
tiatives [4-10].
Over the past few years, extensive studies have been car-
ried out on different systems to regulate transgenes with
small-molecule stimuli, preferentially clinically licensed
agents. Started by the tetraycline-responsive TET system
[11,12], numerous other control modalities have fol-
lowed including those responsive to streptogramin [13],
macrolide [14] and aminocoumarines [15], immunosup-
pressive agents (rapamycin) [16], hormones [17-19], or
susceptible to temperature [20,21], quorum sensing mol-
ecules [22,23] and gaseous acetaldehyde [24]. To date,
most of the experimental work with AAV vectors in the
gene-therapy field has focused on (i) the expression of
therapeutic transgenes driven by strong constitutive pro-
moters [25-27], (ii) the regulated expression of transgenes
based on the tetracycline-responsive TETON and TETOFF
systems [28-31] and, to lesser extent, (iii) the regulated
expression of transgenes by rapamycin-controlled trans-
gene expression [32,33].
Until recently, in-vivo studies using recombinant AAV par-
ticles have been limited by the production of high-titer
and helper virus-free preparations. However, with the
development of helper-free production methods [34,35]
and improved purification and concentration protocols
[36,37], high-titer production of AAV particles in the
absence of helper-virus contamination was achieved,
thereby opening the way to in vivo and clinical studies
with AAV-derived particles.
We report the design and validation of different AAV type
2-based expression vectors, which enable macrolide-con-
trolled transgene expression capitalizing on the recently
developed erythromycin-responsive expression technol-
ogy (E.REX) [14]. E.REX systems exist in two different con-
figurations: (i) the EOFF  arrangement consisting of a
macrolide-dependent transactivator (ET, a fusion of the
Escherichia coli MphR(A) repressor protein [E] and the
Herpes simplex virus VP16 transactivation domain) which
binds and activates chimeric promoters (PETR) assembled
by placing ET-specific operator modules 5' of a minimal
eukaryotic promoter in a macrolide-responsive manner.
Since the presence of erythromycin turns transgene
expression off by abolishing the ET-PETR interaction these
control modalities are known as OFF-type or EOFF systems
[14]. (ii) The EON technology consists of a macrolide-
dependent transrepressor (E-KRAB (ET4), [14]), a fusion
of the E. coli MphR(A) repressor protein [E] and the KRAB
(Krueppel-associated box) transsilencing domain of the
human kox-1 gene), which binds and represses chimeric
promoters (PETRON) assembled by placing E-KRAB-spe-
cific operator modules 3' of a constitutive eukaryotic pro-
moter in a macrolide-inducible manner. Since the
presence of erythromycin turns transgene expression ON
by releasing E-KRAB from PETRON, these control arrange-
ments are known as ON-type or EON systems [14].
We have designed a set of recombinant AAV vectors har-
boring EOFF or EON-controlled expression units (i) on two
independent vectors (binary system), (ii) on a single vec-
tor expressing the transgene and the transactivator in a
dicistronic or bidirectional configuration and (iii) on a
single vector containing a constitutive promoter, driving
transactivator expression, and the regulatable PETR pro-
moter, driving the gene of interest. We have optimized
performance, delivery and regulation, analyzed key char-
acteristics such as reversibility and adjustability of the sys-
tems and validated the results with quantitative in-vitro as
well as mouse studies.
Results
Design of recombinant adeno-associated viral particles for 
transduction of EOFF-controlled transgene expression
We have engineered serotype 2-based adeno-associated
viral particles for transduction of macrolide-responsive
expression of the enhanced yellow fluorescent protein
(EYFP). The generic design consisted of a set of two vec-
tors: pDF51 (ITR-PhCMV-intronβ-globin-ET1-pAHGH-ITR)
harboring an ITR (inverted terminal repeats)-flanked
PhCMV- (human cytomegalovirus immediate early pro-
moter) driven and pAhgh- (human growth hormone-
derived polyadenylation site) terminated ET1 (macrolide-
dependent transactivator) expression unit containing a β-
globin intron (intronβ-globin) reported to increase tran-
script processing and overall ET1 production levels and
pDF54 (ITR-PETR-EYFP-pASV40-ITR) containing an ITR-
flanked expression unit encoding PETR- (macrolide-
responsive promoter) driven and pASV40- (simian virus
40-derived polyadenylation site) terminated EYFP
(enhanced yellow fluorescent protein-encoding gene)
expression cassette (Figure 1A). Transgenic AAV-derived
particles produced by transient co-transfection of either
pDF60, pDF51 or pDF54 with the helper construct pDG
providing constitutive processing and assembly functions
(adenovirus E2A, E4 and VA as well as AAV rep and cap
genes; [38]) in trans into HEK293-T were validated for reg-
ulated EYFP expression by co-transduction of pDF51- and
pDF54-derived AAV particles into representative cell types
such as Chinese hamster ovary cells (CHO-K1), human
fibrosarcoma cells (HT-1080), primary normal human
dermal fibroblasts (NHDF) and human breast cancer cells
(MCF-7) cultivated in the presence (+EM) or absence (-
EM) of the macrolide antibiotic erythromycin (EM). Fluo-
rescence micrographs of transduced populations main-
tained for 48 h in erythromycin-free medium revealedBMC Biotechnology 2007, 7:75 http://www.biomedcentral.com/1472-6750/7/75
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bright green fluorescence in all cell types. Transduced
populations cultivated for two days in the presence of 1
μg/ml erythromycin showed no important EYFP expres-
sion. As a positive control all cell types were transduced
with AAV particles harboring EYFP driven by a constitu-
tive human cytomegolovirus immediate early promoter
(PhCMV) (Figure 1B).
One vector-based macrolide-responsive AAV expression 
vectors
In order to enable delivery of macrolide-responsive trans-
gene expression in a most compact format and a single
transduction event we engineered expression of the mac-
rolide-dependent transactivator ET1 and the desired target
gene into a single AAV vector configuration. The pioneer-
ing one-vector design concept consisted of tandem consti-
tutive ET1 (PSV40-ET1-pASV40) and macrolide-responsive
EYFP expression units (PETR-EYFP-pASV40) placed between
two ITRs (Figure 2A). pDF141- (ITR-PSV40-ET1-pASV40-
PETR-EYFP-pASV40-ITR) derived AAV particles efficiently
transduced HT-1080 and MCF-7 and mediated high-level
EYFP expression when transgenic populations were grown
for 48 h in the absence of erythromycin (Figure 2B). To
prevent any deregulation of PETR by promoters or enhanc-
ers encoded in cis and to minimize the overall size of the
transgene unit, we assembled (i) pDF124 (ITR-PETR-EYFP-
IRESEMCV-ET1-pASV40-ITR) a dicistronic autoregulated
PETR-driven AAV expression configuration harboring an
ITR-flanked PETR-driven dicistronic expression cassette
with EYFP in the first and ET1 in the second cistron sepa-
rated by a internal ribosome entry site of encephalomyo-
carditisviral origin (IRESEMCV) and (ii) pDF89 (ITR-pAI-
EYFP←PhCMVmin-ETR-PHSP70min→ET1-pASV40-ITR) con-
taining a bidirectional expression unit consisting of a cen-
tral ET1-specific operator ETR flanked by PETR driving
EYFP expression in one direction and a PHSP70min (mini-
mal version of the Drosophila melanogaster heat-shock pro-
tein 70 promoter) driving ET1 in the opposite direction.
Following transduction of pDF124-derived AAV particles,
active PETR produces a single transcript from which EYFP is
translated in a classic cap-dependent manner whereas ET1
production depends on cap-independent IRESEMCV-medi-
ated translation initiation. Undetectable PETR-mediated
transcripts result in few initial ET1 proteins, which, in the
absence of erythromycin trigger auto-regulated high-level
expression of this transactivator along with the cocistron-
ically encoded EYFP. In the presence of erythromycin, ET1
originating from basal PETR activity is inactivated, which
interrupts the auto-regulated feed-forward transcription
and results in repression of EYFP production. After trans-
duction of pDF89-derived AAV particles, leaky ET1 tran-
script initiate an auto-regulated expression circuit
resulting in simultaneous expression of ET1 and EYFP
until ET1-ETR binding is abolished by erythromycin. All
three configurations yielded AAV particles, which dis-
played good regulation performance upon trandsduction
of HT-1080 and MCF-7 and cultivation in the absence or
in the presence of erythromycin (Figure 2B). While using
equal genomic particle numbers the transduction effi-
ciency varied between pDF124, pDF89 and pDF141.
Trandsuction rates of the bi-directional (pDF89) and the
dicistronic expression units (pDF124) were significantly
lower compared to the two-promoter set-up (pDF141)
(Fig. 2B) which made FACS-based quantitative analysis
rather difficult (Figure 2C). However qualitative fluores-
cence microscopy suggested excellent regulation perform-
ance in individual transduced cells (Fig. 2B).
Engineered AAV-derived particles transducing tightly 
regulated production of secreted proteins
Tight regulation of therapeutic transgenes remains a
major challenge for current gene therapy initiatives. In
order to assess whether AAV-based transduction systems
enable delivery of tightly regulated expression of a human
model glycoprotein, we constructed pDF77 harboring a
PETR-driven SEAP (human placental secreted alkaline
phosphatase) (ITR-PETR-SEAP-pASV40-ITR) (Figure 3A).
Co-transduction of HT-1080 and MCF-7 with pDF77- and
pDF51- (ITR-PhCMV-ET1-pASV40-ITR) derived AAV particles
provided excellent regulation performance characterized
by high-level SEAP production in the absence of erythro-
mycin and repressed SEAP levels in the presence of eryth-
romycin (Figure 3B). Furthermore, we have designed and
evaluated pDF143 (ITR-PSV40-ET1-pASV40-PETR-SEAP-
pASV40-ITR), a one-vector expression configuration which
is isogenic to pDF141 but encoding SEAP instead of EYFP.
pDF143 exhibited similar SEAP regulation profiles in HT-
1080 and MCF-7 compared to co-transduction of pDF77-
/pDF51-derived AAV particles suggesting that there is no
interference between ET1-driving PSV40 and ET1-specific
PETR (Figure 3A and 3B). Overall, maximum expression
levels for the one-vector configuration were even higher
than for the binary setting likely because for the binary
system two different particles have to transduce a single
cell which is a more rare event. Transduction of HT-1080
and MCF-7 with a constitutive control vector, pDF109
(ITR-PhCMV-intronβ-globin-SEAP-pAhgh-ITR) showed
increased SEAP production compared to fully induced
pDF143-derived particles, which might be associated with
either higher promoter strenght or the β-globin intron.
AAVs engineered for EON-controlled transgene expression
Various therapeutic initiatives require transgene control
systems, which trigger heterologous target genes after
administration of the regulating agent and remain
repressed in the absence of the inducer [39]. We have con-
structed binary EON-controlled AAV-based expression sys-
tems consisting of pDF126 (ITR-PhCMV-Intron-β-globin-E-
KRAB-pAhgh-ITR), and pDF207 (ITR-PETRON8-EYFP-BMC Biotechnology 2007, 7:75 http://www.biomedcentral.com/1472-6750/7/75
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AAV type 2-based macrolide-responsive EYFP expression Figure 1
AAV type 2-based macrolide-responsive EYFP expression. (A) Schematic representation of AAV type 2-based vectors encod-
ing ET1 under control of the constitutive PhCMV promoter (pDF51) and EYFP driven by PETR (pDF54) or a constitutive hCMV 
promoter (pDF60). (B) Fluorescence micrographs of CHO-K1, HT-1080, NHDF and MCF-7 either co-transduced with pDF51/
pDF54 and cultivated in the presence (+) and absence (-) of erythromycin (EM) or transduced with pDF60 (1000 genomic par-
ticles/cell for each vector). Abbreviations: EM, erythromycin; ET1, erythromycin-dependent transactivator; EYFP, enhanced 
yellow fluorescent protein; ITR, inverted terminal repeat; pAhgh, human growth hormone polyadenylation signal; pASV40, simian 
virus 40 polyadenylation signal; PETR, erythromycin-responsive promoter; PhCMV, human immediate early cytomegalovirus pro-
moter; Selected restriction sites: A, AccI; As, AscI; Bg, BglII; Bs, BstBI; Bsa, BsaBI; C, ClaI; E, EcoRI; H, HindIII; Hi, HincII; M, MluI; 
N, NdeI; Nh, NheI; Nr, NruI; P, PacI; Pm, PmeI; Pml, PmlI; S, SalI; Sa, SacII Sp, SpeI; Sph, SphI; Sw, SwaI; X, XbaI.BMC Biotechnology 2007, 7:75 http://www.biomedcentral.com/1472-6750/7/75
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Self- and auto-regulated AAV type 2-based expression of fluorescent proteins Figure 2
Self- and auto-regulated AAV type 2-based expression of fluorescent proteins. (A) Schematic representation of an auto-regu-
lated (pDF124), a bidirectional (pDF89) and a self-regulated (pDF141) AAV type 2-based expression unit. (B) Fluorescence 
micrographs of human fibrosarcoma cells (HT-1080) and a human breast cancer cell line (MCF-7) transduced with pDF124-, 
pDF89- and pDF141-derived AAV particles (2000 genomic particles/cell) cultivated in the presence (+) and absence (-) of EM. 
(C) FACS-mediated quantification of EYFP in HT-1080 transduced with equal amounts of viral particles (2000 genomic parti-
cles/cell) and cultivated in the presence (+EM) and absence (-EM) of erythromycin. Abbreviations: EM, erythromycin; ET1, 
erythromycin-dependent transactivator; ETR, ET1-specific operator; EYFP, enhanced yellow fluorescent protein; IRES, internal 
ribosome entry site; ITR, inverted terminal repeat; pAI, synthetic polyadenylation signal; pASV40, simian virus 40 polyadenylation 
signal; PETR, erythromycin-responsive promoter; PHSP70min, minimal version of the Drosophila melanogaster heat-shock protein 70 
promoter; PSV40, simian virus 40 promoter.BMC Biotechnology 2007, 7:75 http://www.biomedcentral.com/1472-6750/7/75
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AAV type 2-based regulated expression of secreted proteins Figure 3
AAV type 2-based regulated expression of secreted proteins. (A) Schematic representation of pDF77, harboring a SEAP 
expression cassette under the control of PETR, pDF143, a self-regulated expression unit expressing ET1 from PSV40 and driving 
SEAP from PETR and pDF109, harboring a constitutive SEAP expression unit driven by PhCMV (B) SEAP expression levels profiled 
48 h after (co-)transduction of transgenic AAV particles (1000 genomic particles/cell for pDF51/77, 1000 genomic particles/cell 
for pDF143 and 1000 genomic particles/cell for pDF109) derived from indicated vectors and cultivated in the presence (+) or 
absence (-) of EM. SEAP expression is shown in units/liter (U/l) as defined by Schlatter et al. [52]. Abbreviations: EM, erythro-
mycin; ET1, erythromycin transactivator; ITR, inverted terminal repeat; pASV40, simian virus 40 polyadenylation signal; PhEF1α, 
human elongation factor 1α promoter; PETR, erythromycin-responsive promoter; SEAP, human placental secreted alkaline 
phosphatase; PSV40, simian virus 40 promoter.BMC Biotechnology 2007, 7:75 http://www.biomedcentral.com/1472-6750/7/75
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pASV40-ITR), pDF208 (ITR-PETRON4-EYFP-pASV40-ITR) or
pDF209 (ITR-PETRON2-EYFP-pASV40-ITR), which harbor
EYFP under control of different E-KRAB-specific mac-
rolide-inducible promoters characterized by different ETR
tandem repeats placed 3' of the constitutive PSV40 pro-
moter [14]. Functionality of the ON-type system was vali-
dated by co-transduction of pDF126/pDF209-derived
into HT-1080 and MCF-7 and profiling of EYFP expres-
sion after 48 h cultivation in the presence or absence of
erythromycin (Figure 4B). FACS-based comparison of HT-
1080 co-transduced with pDF126-/pDF207-, pDF126-/
pDF208- and pDF126-/pDF209-derived AAV particles
and cultivated for 48 h in the presence and absence of
erythromycin revealed that although overall induction
factors were almost identical among different particle
combinations, basal and maximum expression levels were
a function of the number of ETR repeats associated with
PSV40 (Figures 4A and 4C).
Reversibility and adjustability of AAV-transduced 
macrolide-controlled transgene expression
Reversibility and adjustability are key characteristics for
future clinical implementation of human-compatible
transgene control modalities. In order to assess the revers-
ibility of macrolide-responsive transgene expression in an
AAV expression configuration we transduced HT-1080
and MCF-7 with pDF143-derived AAV particles and culti-
vated (i) in the presence (+++) or absence (---) of EM over
9 days, (ii) in the presence (++-) or absence (--+) of EM
over 6 days and then incubated in reversed EM conditions
for the remaining three days and (iii) in medium whose
EM status was alternated every three days from +EM to -
EM to +EM (+-+) or from -EM to +EM to -EM (-+-). SEAP
accumulation was always measured prior to any EM status
switch.
HT-1080 and MCF-7 showed excellent switching charac-
teristics upon application of removal of erythromycin
(Figure 5A and 5B)
In order to assess the dose-response characteristics of
binary and one-vector-based macrolide-responsive AAV
transduction systems HT-1080 and MCF-7 were trans-
duced with pDF143- or co-transduced with pDF77-/
pDF51-derived AAV particles and cultivated for 48 h in
the presence of different EM concentrations before SEAP
production was quantified. Whereas SEAP expression was
completely repressed between 20 and 100 ng/ml for both
configurations gradual decrease in antibiotic treatment
resulted in dose-dependent increase of transgene expres-
sion until maximum expression levels were reached in the
absence of EM (Figure 5C and 5D). The differences in the
dose-response characteristics of one-vector and binary
configurations may result from different ET1-PETR stoichi-
ometries associated with those technologies.
Transgenic AAV-derived particles mediate EOFF-
controlled transgene expression in mice
For in-vivo validation of AAV-based macrolide-responsive
transgene transduction we injected 5*1010  pDF143-
derived genomic AAV particles intramuscularly into mice
and treated them optionally with intraperitoneal erythro-
mycin injections (2 mg/mouse every 24 h). Profiling of
serum SEAP levels of treated mice showed significant pro-
duction of this glycoprotein in mice, which had not
received EM doses whereas SEAP production was
repressed whenever EM was administered (Figure 6).
Discussion
In recent years, gene delivery systems based on adeno-
associated viral vectors have become one of the most
promising tools for delivering transgenes in vivo. After
major setbacks in trials with retroviral as well as adenovi-
ral vectors [40,41], AAVs present a strong alternative for
the safe and efficient delivery of transgenes. We have pio-
neered the delivery and regulation of transgenes by inte-
grating the recently developed erythromycin-controllable
E.REX system into AAV type 2-derived backbones. Consid-
ering that erythromycin is a clinically licensed drug and
that AAV vectors have an excellent safety profile record,
such a system is suitable for in vivo applications and is
promising for clinical initiatives. Maximum erythromycin
doses of up to 4 g/day in adults are in accordance with
FDA and AHFS guidelines [42,43]. These doses are within
the range of the amounts we have tested in mice. We are
therefore confident that the AAV-encoded and erythromy-
cin-controlled transgenes will be compatible with future
clinical applications.
Research, in which AAV vectors deliver adjustable trans-
genes, has been conducted mainly with tetracycline
responsive systems, which trigger or repress expression
upon the addition of tetracycline [28,29,31,44,45].
We have designed a range of AAV type 2-based vectors
encoding different configurations of the EOFF expression
system to evaluate optimal arrangements for further in
vivo studies. A binary set-up, where the transactivator is
delivered on one vector and the gene of interest is driven
by PETR on another vector, worked well in vitro. The expres-
sion levels, vector titers and regulation performance of the
tested configurations were excellent, indicating an effi-
cient co-transduction of the two types of transgenic AAV
particles. Regardless of whether intracellular or secreted
transgenes were expressed, the regulation factors of all the
tested cell lines were between 10 and 400. Although trans-
gene expression mediated by AAVs engineered for mac-
rolide-responsive transgenes expression were typically
lower after induction compared to isogenic AAV deriva-
tives containing constitutive promoters the overall pro-
duction levels were in the same order of magnitude inBMC Biotechnology 2007, 7:75 http://www.biomedcentral.com/1472-6750/7/75
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AAV type 2-based erythromycin-inducible EYFP expression Figure 4
AAV type 2-based erythromycin-inducible EYFP expression. (A) Schematic representation of pDF126 harboring a PhCMV-driven 
E-KRAB expression unit and pDF206/207/208 encoding EYFP transcribed by PETRON promoter derivatives containing 8 
(pDF207), 4 (pDF208) and 2 (pDF209) E-KRAB-specific ETR operator modules. (B) Fluorescence micrographs of HT-1080 and 
MCF-7 co-transduced with pDF209/pDF126-derived AAV particles (1000 genomic particles/cell for pDF207/208/209 and 4000 
genomic particles/cell for pDF126) and cultivated in the presence (+EM) and absence (-EM) of erythromycin (C) FACS-medi-
ated quantification of EYFP expression in HT-1080. EYFP-specific FACS diagrams of HT-1080 co-transduced (4000 and 1000 
genomic particles/cell) by pDF126/pDF207, pDF126/pDF208 and pDF126/pDF209 were cultivated for 48 h in the presence (+) 
and absence (-) of EM. Abbreviations: EM, erythromycin; EYFP, enhanced yellow fluorescent protein; ITR, inverted terminal 
repeat; KRAB, kruppel associated box; PETRON, erythromycin-inducible promoter.BMC Biotechnology 2007, 7:75 http://www.biomedcentral.com/1472-6750/7/75
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vitro. Isogenic EON systems also enabled excellent regula-
tion performance but overall induction factors were typi-
cally lower, since cells exclusively transduced with the
transgene-encoding AAV particle exhibit constitutive
expression. Therefore, to achieve optimized EON-control-
led transgene expression from transgenic AAVs arranged
in a binary vector set, the transrepressor-encoding AAV
has to be administered in excess compared to the trans-
gene-encoding counterpart or cell lines have to be used,
which are particular susceptible to AAV-based transduc-
tion.
Generally, even though binary systems have the disadvan-
tage that two vectors must enter the same cell to obtain
regulated expression, this design is advantageous for some
applications, namely when delivering large transgenes.
Although binary systems are powerful tools, in a thera-
peutic setting it may be desirable to combine the regula-
tion modules on a single vector. The advantages of such a
setting are: (i) only one virus must enter the target cell to
obtain regulated expression of the transgene, (ii) exact
virus titration is easier and (iii) lower virus doses are
required for comparable transgene expression.
Reversibility and adjustability of macrolide-responsive SEAP expression in HT-1080 and MCF-7 transduced by transgenic AAV  type 2-derived particles Figure 5
Reversibility and adjustability of macrolide-responsive SEAP expression in HT-1080 and MCF-7 transduced by transgenic AAV 
type 2-derived particles. (A) HT-1080 and (B) MCF-7 were transduced with pDF143-derived AAV particles (2000 genomic par-
ticles/cell) and six equal populations (1–6) were cultivated in media containing different antibiotic concentrations. Cells were (i) 
cultivated in the presence (+++) or absence (---) of EM over 9 days, (ii) cultivated in the presence (++-) or absence (--+) of EM 
over 6 days and then incubated in reversed EM conditions for the remaining three days or (iii) cells were cultivated in medium 
whose EM status was alternated every three days +EM to --EM to +EM (+-+) or from --EM to +EM to --EM (-+-) and SEAP 
expression was quantified. Adjustability of SEAP expression of pDF143 (1000 genomic particles/cell) (C) and pDF51/77 (500 
genomic particles/cell) (D) in HT-1080 and MCF-7 cultivated for 48 h in the presence of increasing EM concentrations. SEAP 
expression is shown in units/liter (U/l) as defined by Schlatter et al. [52]. Abbreviations: EM, erythromycin; SEAP, human pla-
cental secreted alkaline phosphatase. Abbreviations: EM, erythromycin; SEAP, human placental secreted alkaline phosphatase.
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We have pioneered both self-regulated and auto-regulated
macrolide-responsive recombinant adeno-associated viral
vectors for tightly controlled transgene expression.
Although auto-regulated expression units are more com-
pact than self-regulated configurations we had difficulty
achieving reasonably high transduction efficiencies and
expression levels. Since qRT-PCR-based analysis of viral
particles revealed identical number of encapsidated
genomes among our AAV portfolio, the lower transduc-
tion rates of auto-regulated AAVs may result from their
genetic configuration rather than virus assembly. In con-
trast, self-regulated expression units, consisting of a strong
constitutive promoter driving the expression of the trans-
activator as well as a macrolide-responsive promoter driv-
ing the desired transgene on the same vector, showed
excellent performance in a variety of cell types. The vector
design using compact promoter and polyadenylation ele-
ments in a self-regulated configuration allows the integra-
tion of a transgene with a size of up to 2500 bp which is
sufficient for various clinically important transgenes (for
example, erythropoietin or vascular endothelial growth
factor). We did not observe promoter interference in the
tested cell types, although the strong constitutive PSV40
promoter driving ET1 and the erythromycin-responsive
promoter were on the same construct. We were successful
in expressing intracellular as well as secreted transgenes in
a highly controlled manner and showed precise titration
of transgene expression upon addition of varying erythro-
mycin concentrations as well as reversibility upon the
addition or removal of the regulating agent. After switch-
ing from a fully repressed to a fully induced state or vice
versa  a short lag phase was observed before the new
expression state was reached. This behaviour might be due
to trace amounts of antibiotic remaining in the culture (by
switching from +EM to -EM) or due to the degradation
kinetics of transcripts and transactivators (from -EM to
+EM)
One-vector configurations would be suitable for in vivo
studies and would enable efficient targeting of a wide vari-
ety of cells by systemic administration or by local injec-
tion of the viral particles encoding the therapeutic
transgene. We exemplified the functionality of the system
in vivo by administrating pDF143-derived AAV particles
intramuscularly to mice and analyzing transgene expres-
sion in the presence and absence of antibiotic for several
days.
Most current studies on regulated transgene expression are
carried out using retroviral vectors [46-50]. Although
these systems are powerful and allow the efficient long-
term expression of transgenes, they have several draw-
backs, such as (i) the necessity of retroviral vectors for
integration into transcriptionally active regions, which
may interfere with desired transgene control, (ii) random
integration, possibly triggering oncogene activation and
(iii) silencing of the integrated transgene upon integration
into the host chromosome. Adeno-associated viral vectors
on the contrary, remain mainly episomal after entering
the target cell and, therefore, do not have aforementioned
drawbacks, thus providing a powerful alternative for
upcoming gene-therapy studies.
Conclusion
We have designed an array of novel AAV type 2-based
expression vectors, which enable safe and efficient trans-
duction of mammalian cells for macrolide-adjustable
transgene expression. We have pioneered binary ON- and
OFF-type systems as well as compact bidirectional, auto-
regulated and self-regulated one vector expression config-
Macrolide-triggered SEAP expression in mice injected with  pDF143 (ITR-PSV40-ET1-pASV40-PETR-SEAP-pASV40-ITR)- derived AAV type 2 particles Figure 6
Macrolide-triggered SEAP expression in mice injected with 
pDF143 (ITR-PSV40-ET1-pASV40-PETR-SEAP-pASV40-ITR)-
derived AAV type 2 particles. pDF143-derived AAV particles 
were administered intramuscularly and SEAP levels in the 
serum were measured at two different time points for one 
group in the absence of erythromycin, and for the other 
group with EM injections every 24 h. SEAP expression is 
shown in milliunits/liter (mU/l) as defined by Schlatter et al. 
[52]. Abbreviations: EM, erythromycin; SEAP, human placen-
tal secreted alkaline phosphatase.BMC Biotechnology 2007, 7:75 http://www.biomedcentral.com/1472-6750/7/75
Page 11 of 15
(page number not for citation purposes)
urations for regulation of intracellular as well as secreted
proteins in mammalian cells. We have also engineered a
compact self-regulated AAV which demonstrated efficient
transduction, expression and regulation of a reporter gene
in mice.
Methods
Plasmid construction
Table 1 lists all the plasmids used in this study as well as
detailed information on their construction and the length
of the genetic elements.
Cell culture and transfection
Human embryonic kidney cells, transgenic for the adeno-
virus type 5-derived E1 region as well as for the simian
virus 40 (SV40) large T-antigen (HEK293-T; [51]), human
fibrosarcoma cells (HT-1080; ATCC CCL-121), human
breast cancer cells (MCF-7, ATCC HTB-22) and normal
human dermal fibroblasts (NHDF; PromoCell, Heidel-
berg, Germany; cat. no. C-12300, lot no. 1070402) were
cultivated in Dulbecco's modified Eagle's medium
(DMEM, Invitrogen, Carlsbad, CA, USA) supplemented
with 10% fetal calf serum (FCS; PAN Biotech GmbH, Aid-
enbach, Germany; cat. no. 3302-P231902, lot no.
P231902) and 1% penicillin/streptomycin solution
(Sigma Chemicals, St. Louis, MO, USA). Chinese hamster
ovary cells (CHO-K1; ATCC CCL-61) were cultivated in
ChoMaster®  HTS medium (Cell Culture Technologies
GmbH, Gravesano, Switzerland) supplemented with 5%
FCS (PAN Biotech GmbH) and 1% penicillin/streptomy-
cin solution. All cell lines were cultivated at 37°C in a 5%
CO2-containing humid atmosphere.
Production of adeno-associated viral particles
AAV particles were produced by co-transfection of the
helper plasmid pDG [38] and the transgene-encoding
AAV vector into HEK293-T using optimized calcium phos-
phate transfection protocols. In brief, 2 × 106 HEK293-T
were seeded per culture dish (diameter 10 cm) and culti-
vated overnight. For each plate 15 μg of helper plasmid
were mixed with 5 μg AAV vector and CaCl2 was added to
a final concentration of 0.25 M. The mixture was added
slowly to an equal volume of HEPES-buffered saline solu-
tion (HeBS; 50 mM HEPES, 280 mM NaCl, 1.5 mM
Na2HPO4, pH 7.1), vortexed briefly, and incubated for 2
min. before adding the DNA-calcium phosphate precipi-
tate solution to the monolayer culture. Precipitates were
removed after 6 h, cells were supplemented with 1% FCS-
supplemented DMEM and incubated for 60 h. The super-
natant was discarded, the cells were detached using a cell
scraper and resuspended in 2 ml PBS (138 mM NaCl, 8.1
mM Na2HPO4, 1.47 mM KH2PO4, 2.67 mM KCl; Invitro-
gen, cat. no. 21600-069, lot. no. 1255481) per plate. Each
cell suspension was transferred to a Falcon tube and pel-
leted by centrifugation for 3 min. at 280 × g. Following
another washing step using 5 ml PBS, the cells were resus-
pended in 2 ml PBS and the intracellular viral particles
were released after cell lysis induced by three consecutive
freeze-thaw cycles consisting of shuttling the tubes
between liquid nitrogen and a 37°C water bath (tubes
were vortexed vigorously after each thawing step). The cell
debris was eliminated by centrifugation for 5 min. at
10'000 × g and the supernatant containing the crude virus
stock was collected, supplemented with 50 U/ml of Ben-
zonase (Sigma, cat. no. E1014) and incubated for 30 min
at 37°C. Iodixanol density-gradient purification of viral
particles was performed using a protocol adapted from
Zolotukhin et al. [37]. In brief, crude viral stocks were
diluted in PBS to a final volume of 12 ml. Iodixanol step
gradients were prepared in an ultracentrifuge tube by
sequential underlaying of the crude viral preparation with
5 ml of a 15% (plus 1 M NaCl in the first layer), 5 ml of a
25%, 4 ml of a 40% and 4 ml of a 60% iodixanol-contain-
ing PBS. For better distinction of the gradient layers 2.5 μl/
ml of a 0.5% Phenol Red (Sigma, cat. no. P0290) stock
solution was added to the 60% and the 25% layers. Step
gradients were centrifuged for 3.5 h at 150'000 × g at
18°C. The clear 40% fraction was harvested after punctur-
ing the ultracentrifuge tube on the side with a syringe
equipped with a 16G needle. A heparin affinity column
(HiTrap Heparin HP, Amersham Biosciences, Sweden; cat.
no. 17-0406-01) was equilibrated with 10 bed volumes of
binding buffer (10 mM Na2PO4, pH 7) and run at a flow
rate of 1 ml/min. The AAV particle-containing 40% frac-
tion harvested from the step gradient was loaded onto the
heparin affinity column. After washing the column with
10 bed volumes of binding buffer the viral particles were
eluted with 5 bed volumes of elution buffer (10 mM
Na2PO4, 1 M NaCl, pH 7) and then concentrated using a
spin column with a molecular weight cut-off (MWCO) of
30 kDa (Vivaspin, Vivascience, Germany; cat. no.
VS1521).
Virus titration by quantitative real-time PCR
Crude viral preparations were treated as described in [36].
Primers and the Taqman probe were designed to anneal to
(i) the SV40 polyadenylation signal (pA) (forward primer,
5'-AGCAATAGCATCACAAATTTCACAA-3', reverse
primer, 5'-GACATGATAAGATACATTGATGAGTTTGG-3',
Taqman FAM/TAMRA probe, 5'-AGCATTTTTTTCACT-
GCATTCTAGTTGTGGTTTG-3'), (ii) the SEAP open read-
ing frame (forward primer, 5'-AGGCCCGGGACAGGAA-
3', reverse primer, 5'-GCCGTCCTTGAGCACATAGC-3') or
(iii) the erythromycin-dependent transactivator open
reading frame (forward primer, 5'-CCAACTCCTCCAG-
GCACA-3', reverse primer, 5'-AGCAGGCCCTCGAT-
GGTA-3'). Absolute quantification was performed using
Taqman Universal PCR Master Mix (Applied Biosystems,
Warrington, UK, cat. no. 4324018) or Power SYBR Green
PCR Master Mix (Applied Biosystems, Warrington, UK,BMC Biotechnology 2007, 7:75 http://www.biomedcentral.com/1472-6750/7/75
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Table 1: Plasmids used and designed in this study
Plasmid Description and Cloning Strategy Reference or source
pAAV-MCS AAV transfer vector Stratagene
pAAV-lacZ AAV vector expressing lacZ Stratagene
pDG Helper construct encoding AAV Rep/Cap as well as Adeno virus E2A, E4 and VA. [38]
pCF18 Plasmid containing ECFP driven by a tetracycline responsive promoter and EYFP driven by a pristinamycin 
responsive promoter
[53]
pCF19 Plasmid containing SEAP cassette [54]
pCF125 Plasmid expressing ECFP and ET1 from a bidirectional promoter [21]
pSS134 Plasmid containing SEAP cassette unpublished
pWW43 Plasmid expressing E-KRAB [14]
pWW76 Plasmid containing tricistronic expression configuration driven by PETRON8 [14]
pWW78 pTRIDENT1-based tricistronic expression vector for macrolide-responsive auto-regulated expression of up to 
two desired transgenes.
[55]
pBP141 Vector expressing SEAP and ET1 under tetracycline-responsive promoter: PhCMV*-1-SEAP-IRESPV-ET-pA unpublished
pMF123 Plasmid encoding tricistronic expression cassette driven by a constitutive SV40 promoter. [56]
pMF351 Lentiviral vector encoding EYFP driven by a constitutive hCMV promoter [51]
pDF37 AAV2 vector containing a tricistronic PETR driven expression unit. The entire expression unit from pWW73 
was excised using SspI/XbaI, polished by Klenow and cloned into pAAV-lacZ which was NotI digested and 
Klenow polished before, thus resulting in pDF37 (ITR-PETR-IRESPV-IRESEMCV-pASV40-ITR).
this work
pDF51 AAV2 vector containing a constitutive hCMV driven ET1 cassette. ET1 was excised from pWW078 using 
EcoRI/HindIII and cloned into the corresponding sites of pAAV-MCS, thus resulting in pDF51 (ITR-PETR-Intronβ-
globin-ET1-pAhgh-ITR).
this work
pDF54 AAV2 vector encoding EYFP driven by the erythromycin responsive PETR promoter. PETR was excised from 
pDF55 using AccI/NheI and cloned into the corresponding sites of pDF60, thus resulting in pDF54 (ITR-PETR-
EYFP-pASV40-ITR).
this work
pDF55 AAV2 vector encoding divergent expression units for ECFP driven by PETR and ET1 driven by a HSP70 minimal 
promoter. The entire expression cassette was excised from pCF125 using EcoRV/XbaI and cloned into the 
HincII/SpeI sites of pDF60, thus resulting in pDF55 (ITR-pAI-ECFP←PETR-ETR-PHSP70min→ET1-pASV40-ITR).
pDF56 AAV2 vector encoding ET1 driven by a constitutive SV40 promoter. ET1 was excised from pWW78 using 
EcoRI/XbaI and cloned into the EcoRI/SpeI sites of pDF63, thus resulting in pDF56 (ITR-PSV40-ET1-pASV40-ITR).
this work
pDF60 AAV2 vector encoding EYFP driven by a constitutive hCMV promoter. PhCMV-EYFP was excised from pMF351 
using XbaI/PacI and cloned into NheI/PacI sites of pDF63, thus resulting in pDF60 (ITR-PhCMV-EYFP-pASV40-ITR).
this work
pDF61 AAV2 vector encoding SEAP driven by an erythromycin responsive PETR promoter. SEAP was excised from 
pCF019 using NheI/ClaI and cloned into the NheI/BstBI sites of pDF54, thus resulting in pDF61 (ITR-PETR-SEAP-
pASV40-ITR).
this work
pDF63 AAV2 vector containing an SV40 promoter followed by an IRESPV and a IRESEMCV element. PSV40-IRESPV-
IRESEMCV was excised from pMF123 using SspI/BglII, polished with Klenow and cloned into the polished NcoI/
SpeI sites of pAAV-lacZ, thus resulting in pDF63 (ITR- PSV40-IRESPV-IRESEMCV-pASV40-ITR).
this work
pDF74 AAV2 vector containing tricistronic expression cassette driven by a PETRON8 promoter. The PETRON8 
promoter was excised from pWW76 using NheI/EcoRI and cloned into the corresponding sites of pDF63, thus 
resulting in pDF74 (ITR-PETRON8-IRESPV-IRESEMCV-pASV40-ITR).
this work
pDF75 AAV2 vector encoding dicistronic expression unit consisting of SEAP followed by an IRESPV element followed 
by ET1 driven by PETR. Dicistronic expression cassette was excised from pBP141 using XbaI/PacI and cloned 
into the NheI/PacI sites of pDF54, thus resulting in pDF75 (ITR-PETR-SEAP-IRESPV-ET1-pASV40-ITR).
this work
pDF76 AAV2 vector encoding SEAP driven by a PETRON8 promoter. SEAP was excised from pSS134 using EcoRI/
HindIII and cloned into pDF37. This vector was digested using EcoRI/AscI and the SEAP containing insert was 
cloned into the corresponding sites of pDF74, thus resulting in pDF76 (ITR-PETRON8-SEAP-IRESEMCV-pASV40-
ITR).
this work
pDF77 AAV2 vector encoding SEAP under the control of an erythromycin responsive PETR promoter (additional 
upstream ATG deleted). PETR was excised from pDF54 using AccI/EcoRI and cloned into the ClaI/EcoRI sites of 
pDF61, thus resulting in pDF77 (ITR-PETR-SEAP-pASV40-ITR)
this work
pDF89 AAV2 vector encoding divergent expression units for EYFP driven by PETR and ET1 driven by a HSP70 minimal 
promoter. The EYFP cassette was excised from pCF18 using AccI/EcoRV and cloned into the NruI/ClaI sites of 
pDF55, thus resulting in pDF89 (ITR-pAI-EYFP←PETR-ETR-PHSP70min→ET1-pASV40-ITR)
this work
pDF98 Plasmid containing hEF1α promoter flanked by multiple cloning sites unpublished
pDF109 AAV2 vector encoding SEAP driven by a constitutive hCMV promoter. SEAP was excised from pDF61 using 
EcoRI/SpeI and cloned into the EcoRI/XbaI sites of pAAV-MCS, thus resulting in pDF109 (ITR-PhCMV-Intronβ-
globin-SEAP-pAhgh-ITR)
pDF124 AAV2 vector encoding dicistronic expression unit consisting of EYFP followed by an IRESEMCV element 
followed by ET1. The IRES-ET1 containing insert was excised from pDF75 using HindIII, polished with Pfu 
polymerase, digested using BstXI and cloned into the SwaI/BstXI sites of pDF54, thus resulting in pDF124 (ITR-
PETR-EYFP-IRESEMCV-ET1-pASV40-ITR).
this workBMC Biotechnology 2007, 7:75 http://www.biomedcentral.com/1472-6750/7/75
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pDF126 AAV2 vector encoding E-KRAB under the control of a constitutive hCMV promoter. The E-KRAB containing 
insert was excised from pWW043 using EcoRI/HpaI and cloned into the EcoRI/HincII sites of pAAV-MCS, thus 
resulting in pDF126 (ITR-PhCMV-Intronβ-globin-E-KRAB-pAhgh-ITR).
this work
pDF141 AAV2 vector encoding self-regulated expression cassette consisting of ET1 driven by a constitutive SV40 
promoter and EYFP driven by PETR. The entire ET1 expression cassette of pDF56 was excised using ClaI/PmlI 
and cloned into pDF54 which was digested by HindIII and polished by Pfu before, thus resulting in pDF141 (ITR-
PSV40-ET1-pASV40-PETR-EYFP-pASV40-ITR).
this work
pDF143 AAV2 vector encoding self-regulated expression cassette consisting of ET1 driven by a constitutive SV40 
promoter and SEAP driven by PETR. The SEAP containing insert was excised from pDF77 using KpnI/SpeI and 
cloned into the corresponding sites of pDF141, thus resulting in pDF143 (ITR-PSV40-ET1-pASV40-PETR-SEAP-
pASV40-ITR).
this work
pDF199 AAV2 vector encoding SEAP under the control of a constitutive SV40 promoter followed by 2 binding sites for 
the transrepressor E-KRAB. The 4*ETR binding site containing fragment was excised from pWW55 using 
BstBI/NdeI and cloned into the corresponding sites of pDF76. Two of the binding sites were deleted by 
recombination during the cloning procedure, thus resulting in pDF199 (ITR-PETRON2-SEAP-IRESEMCV-pASV40-
ITR).
this work
pDF200 AAV2 vector encoding SEAP under the control of a constitutive SV40 promoter followed by 4 binding sites for 
the transrepressor E-KRAB. The 4*ETR binding site-containing fragment was excised from pWW55 using 
BstBI/NdeI and cloned into the corresponding sites of pDF76, thus resulting in pDF200 (ITR-PETRON4-SEAP-
IRESEMCV-pASV40-ITR).
this work
pDF207 AAV2 vector encoding EYFP under the control of a constitutive SV40 promoter followed by 8 binding sites for 
the transrepressor E-KRAB. EYFP was excised from pDF34 using EcoRI/PacI and cloned into the corresponding 
sites of pDF76, thus resulting in pDF207 (ITR-PETRON8-EYFP-pASV40-ITR).
this work
pDF208 AAV2 vector encoding EYFP under the control of a constitutive SV40 promoter followed by 4 binding sites for 
the transrepressor E-KRAB. EYFP was excised from pDF34 using EcoRI/PacI and cloned into the corresponding 
sites of pDF200, thus resulting in pDF208 (ITR-PETRON4-EYFP-pASV40-ITR).
this work
pDF209 AAV2 vector encoding EYFP under the control of a constitutive SV40 promoter followed by 2 binding sites for 
the transrepressor E-KRAB. EYFP was excised from pDF34 using EcoRI/PacI and cloned into the corresponding 
sites of pDF199, thus resulting in pDF209 (ITR-PETRON2-EYFP-pASV40-ITR).
this work
Abbreviations: AAV2, adeno-associated virus type 2; ECFP, enhanced cyan fluorescent protein (720 bp); EM, erythromycin; ET1, erythromycin 
transactivator (972 bp); EYFP, enhanced yellow fluorescent protein (720 bp); IRESEMCV, internal ribosome entry site of encephalomyocarditisviral 
origin (502 bp); IRESPV, internal ribosome entry site of polioviral origin (635 bp); ITR, inverted terminal repeat (141 bp); KRAB, kruppel-
associated box (450 bp); pAI, artificial polyadenylation signal (91 bp); pAhgh, human growth hormone polyadenylation signal (478 bp); pASV40, 
simian virus 40 polyadenylation signal (145 bp); PhEF1α, human elongation factor 1α promoter (1185 bp); PETR, erythromycin responsive promoter 
(200 bp); PETRON, macrolide inducible promoter (530 bp); PhCMV, human immediate early cytomegalovirus promoter (663 bp); PHSP70min, heat 
shock protein 70 minimal promoter (350 bp); PSV40, simian virus 40 promoter (308 bp); SEAP, human placental secreted alkaline phosphatase 
(1560 bp)
Table 1: Plasmids used and designed in this study (Continued)
cat. no. 4367659) on AB Prism 7500 RT-PCR quantitative
PCR hardware according to the manufacturer's instruc-
tions (Applied Biosystems, Weiterstadt, Germany). The
reference standard consisted of a four log-spanning dilu-
tion of pDF60 harboring a single SV40 pA sequence,
pDF51 harboring the ET1 transactivator or pDF109 har-
boring the SEAP open reading frame.
Quantification of reporter gene expression
Enhanced yellow fluorescent protein (EYFP) was visual-
ized using a Leica DM-RB fluorescence microscope (Leica
Inc., Heerbrugg, Switzerland) equipped with an XF114 fil-
ter (Omega Optical Inc., Brattleboro, VT, USA). Fluores-
cence was quantified 48 h after transduction using a
fluorescence-activated cell sorter (Coulter FC500, Beck-
man Coulter Inc., FL, USA) with CXP software (Beckman
Coulter) installed. SEAP production was quantified in
cell-culture supernatants 48 h after transduction and in
mouse serum 3 days to 7 days after injection as described
in [52].
Chemicals used for transgene regulation
For all in-vitro experiments, erythromycin (Fluka, Buchs,
Switzerland cat. no. E-5389) was prepared as a stock solu-
tion of 1 mg/ml in ethanol and used at a final concentra-
tion of 1 μg/ml. For in-vivo studies, 200 μl of a 10 mg/ml
erythromycin solution (10% ethanol, 90% PBS) were
daily intraperitoneally injected into each animal.
In vivo studies
Female OF1 (oncins france souche 1) mice were obtained
from Charles River Laboratories (Lyon, France). Mice were
treated with intramuscular injections 5 × 1010  vector
genomes/mouse. Erythromycin was administered intra-
peritoneally 1 h after injection of the transgenic AAV par-
ticles and repeated every 24 h. Blood samples were
collected retroorbitally and serum was produced using
microtainer SST tubes (Beckton Dickinson, Plymouth,
UK). All animal experiments were approved by the French
Ministry of Agriculture and Fishery and performed by
M.D.-E. at the Institut Universitaire de Technologie, IUTA,
F-69622 Villeurbanne Cedex, France.BMC Biotechnology 2007, 7:75 http://www.biomedcentral.com/1472-6750/7/75
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